Inactive Instrument

Versartis Inc Stock price Nasdaq

Equities

US92529L1026

Biotechnology & Medical Research

Dynamic Chart

Latest transcript on Versartis Inc

Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 22-06-30
Chief Operating Officer 51 22-03-20
Director/Board Member 61 18-09-30
Members of the board TitleAgeSince
Director/Board Member 61 18-09-30
Chairman 76 20-04-07
More insiders
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
More about the company
  1. Stock
  2. Equities
  3. Stock Aravive, Inc.
  4. Stock Versartis Inc - Nasdaq